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ABSTRACT 
 
 
COMPUTATIONAL MODEL OF ALENDRONATE EFFECTS ON CANINE RIB 
REMODELING AND MICRODAMAGE 
 
 
Emily Huang 
 
 
Bisphosphonates are a class of drugs used to prevent and treat bone diseases by 
inhibiting the resorption of bone by osteoclasts and suppressing bone remodeling.  
Osteoporosis is a bone disease that develops when bone resorption exceeds bone 
formation which results in an increase in bone porosity and fracture risk.  The risk for 
fractures can be reduced by increasing bone mass.  Alendronate is type of bisphosphonate 
that is approved by the Food and Drug Administration (FDA) to treat postmenopausal 
osteoporosis by suppressing basic multicellular unit (BMU) remodeling and increasing 
bone mass.  The long term effects of bisphosphonates are still unclear due to the 
difficulty in obtaining long term data; therefore, developing a mathematical model based 
on data and relationships from short term studies can be a useful method in predicting the 
effects of the drug. 
The purpose of this study was to develop a computer model that could simulate 
the long term effects of alendronate treatment on canine rib remodeling, bone volume, 
and microdamage by matching 1 and 3 year experimental data results.  The experimental 
effects of alendronate (ALN) were studied at the Indiana University School of Medicine.  
In two separate experiments, skeletally mature female beagles were subjected to 1 and 3 
year treatments of saline vehicle (CON), or one of two doses of ALN (ALN0.2 or 
ALN1.0 mg/kg/day).  The lower dose (ALN0.2) corresponds to the clinical dosage used 
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to treat postmenopausal osteoporosis and the higher dose (ALN1.0) is the dose used to 
treat Paget’s disease.  Bone volume fraction (BV/TV), damage, and remodeling 
activation frequency (Ac.f) of the rib were quantified using standard histomorphometric 
techniques.  
 The mathematical model was developed by modifying a previous mathematical 
algorithm for trabecular bone remodeling, to create an equilibrium for cortical bone 
remodeling that matched the experimental control data from 1 year studies.  Using the 
equilibrium conditions as a baseline model, ALN was modeled by suppressing activation 
frequency and reducing the resorption area.  The changes in BV/TV, damage 
accumulation, and Ac.f were followed for 3 years and compared to the experimental 
results.  The results for BV/TV, Ac.f, and damage for the 1 year model and the results for 
BV/TV and damage for the 3 year model were consistent with experimental studies.  
BV/TV results for both doses showed increases from 1 to 3 years with alendronate 
treatment.  Ac.f results for both treatment doses at 1 year and ALN1.0 at 3 years were 
also within range of the experimental data; however, ALN0.2 for 3 years was not 
consistent with the experimental results. While the predicted Ac.f for ALN0.2 does show 
an initial decrease, it is not nearly as extreme as the results from the experimental data 
and the data remains fairly constant between 1 and 3 years, which is in contrast to the 
experimental results.  The model also predicts damage accumulation is greatest early 
during bisphosphonate treatment, due to the initial suppression of bone resorption.  This 
increase in microdamage accumulation was previously thought to impair the mechanical 
properties of bone; however, recent experimental studies show that while the initial 
increase in microdamage may contribute to alterations in bone properties at 1 year of 
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treatment, other factors appear to contribute to their reduction long term. The simulation 
results are consistent with the experimental data, which suggest that damage increases for 
up to 1 year of treatment and then levels off thereafter. The results of the simulation 
suggest that since bisphosphonates do not cause further increases in microdamage 
accumulation after 1 year of treatment, ALN may not lead to increased bone fragility 
associated with microdamage long term and rather, may decrease fracture risk.   
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4 
CHAPTER 1: INTRODUCTION 
 
 
 
1.1 Properties of Bone 
 
Bone is a dynamic structure whose properties make it ideal for structural support, 
protection, mineral storage, movement, and cell formation.  The properties of bone allow 
it to adapt to its surrounding environment and optimize its structure in order to maintain 
its light weight and strength. Bone is a specialized connective tissue made up of an 
extracellular matrix (ECM) and a cellular component. The ECM is responsible for the 
functional characteristics of bone tissue like structure and strength and is made up of both 
organic and inorganic material.  The organic material consists mostly of collagen and the 
inorganic material consists primarily of hydroxyapatite or calcium phosphate crystals.  
The ECM is the mineralized portion of bone and is maintained by living cells that form 
the cellular component [1].   
 
 
1.2 Bone tissue 
  
Bone tissue can be classified as either cortical or trabecular bone depending on its 
porosity (Figure 1). Cortical bone, also referred to as compact bone, forms a very dense 
cortex around bone with porosities between 5 to 10 percent [2]. The key feature of 
compact bone is a functional unit called an osteon which is made up of closely packed 
concentric circular matrices called lamellae. The cylindrical geometry of an osteon makes 
cortical bone more resistant to fractures because the energy required to form a crack is 
dissipated along the outer cement line of the circular osteon thus slowing down and even 
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stopping crack propagation.  This characteristic gives cortical bone a fracture toughness 
of 2.2-6.3 MPa-m1/2, elastic modulus of 17.4 GPa, and a high tensile ultimate stress of 
133 MPa [1]. Enclosed in the center of an osteon is the Haversian canal which contains 
nerves and blood vessels that are essential for providing nutrients and removing wastes 
from the surrounding cells [2]. Compact bone also consists of Volkman’s canals and 
resorption cavities.  The Volkman’s canals contain blood vessels that connect the 
Haversian canals to each other and to the bone surface while the resorption cavities are 
temporary spaces created by osteoclasts during bone remodeling [2].  The porosity of 
cortical bone is largely made up of these Haversian canals, Volkmann’s canal, and 
resorption cavities (Figure 2).  Trabecular bone, also called cancellous or spongy bone, 
consists of a network of interconnected struts called trabeculae which are surrounded by 
bone marrow (Figure 3).  In contrast to cortical bone, trabecular bone consists of a more 
irregular structure, making the bone more fragile with an elastic modulus of 272 ± 195 
MPa and an ultimate stress of 2.54 ± 0.62 MPa [2].  Compared to cortical bone, 
trabecular bone is highly porous and more loosely packed with porosities between 75 to 
95 percent [2].  
 
 
 
 
 
Figure 1. Illustration of important features in both cortical and trabecular bone [3]. 
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Figure 2. Microphotograph of cortical bone including important features like the 
osteons, Haversian canals, and Volkmann’s canals [46]. 
 
 
Figure 3. Microphotograph of normal trabecular bone [47]. 
 
1.3 Bone Cells 
  
The formation of the ECM is due to a collection of bone cells that maintain the 
matrix.  As bone tissue is constantly being loaded, bone cells must work together to 
remove any fatigue damage caused by stress in order to maintain the integrity of the bone 
[2].  The cellular component of bone consists of four main cells which can be categorized 
into two cell types: bone resorbing and bone forming.  Cells that resorb bone are similar 
Haversian Canal 
Volkmann’s Canal 
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to macrophages whose main role is to phagocytose or remove debris. Cells that form 
bone are like fibroblasts, whose role is to synthesize and maintain the bone matrix. The 
four bone cells are osteoclasts, osteocytes, osteoblasts, and bone lining cells (Figure 4).  
Osteoclasts are multinucleated cells made in the bone marrow and are responsible 
for bone resorption.  The area of contact between the osteoclasts and the bone matrix 
forms a ruffled or brushed border where resorption occurs.  Hydrogen ions and enzymes 
are released along this border to demineralize and dissolve the proteins in the matrix [1]. 
Osteoblasts are bone forming cells found on the border of developing bone.  They 
are mononucleated cells made in the bone marrow and are thought to be activated by 
mechanical stress [2].  These cells produce an unmineralized matrix called osteoid which 
is made primarily of type 1 collagen.  The apposition rate or the rate at which the osteoid 
is laid down is about 1 micrometer/day [2].  As the amount of osteoid increases, the 
osteoblasts get pushed into the developing matrix and become osteocytes.    
Osteocytes are mature osteoblasts located within the bone matrix and are thought 
to play a role in bone turnover by sensing mechanical stress [2].  These cells are 
embedded in cavities called lacunae and can communicate with other osteocytes and 
osteoblasts through canals called canaliculi [1].  The canaliculi form tight gap junctions 
within the bone in which nutrients and chemical signals are passed [2].  This network of 
communication allows the osteocytes to transmit information and play an important role 
in bone remodeling.  
After osteoblasts have completed filling in a cavity, the cells flatten out and 
“retire”, becoming bone lining cells [2].  Bone lining cells, like osteocytes, are made from 
osteoblasts; however, unlike osteocytes, these cells do not get buried into the bone matrix 
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but rather, become dormant and flatten out discontinuously against the bone surface.  
Bone lining cells communicate with osteocytes through gap junctions and are thought to 
regulate the movement of minerals like calcium and phosphate into and out of the bone. 
These cells are also believed to be able to sense changes in mechanical stress and 
chemical stimuli in order to activate the remodeling process [2].  
 
 
 
 
Figure 4. Schematic of bone cells. The osteoclasts are characterized as being multinucleated 
and having a ruffled border along the area of contact with the bone.  Osteoblasts form bone 
by producing an unmineralized bone tissue called osteoid which will later become calcified 
bone matrix. Both osteocytes and bone lining cells are derived from osteoblasts and are 
either embedded into the matrix (osteocytes) or flattened over the bone surface (bone lining 
cells) and play a role in the remodeling process [3]. 
 
 
 
1.4 Bone Modeling and Remodeling 
 
Wolff’s law states that bone is a dynamic structure that is able to sense 
mechanical loads and adapt its structure to match the surrounding environment [2].  Bone 
adaptation is accomplished by two processes called modeling and remodeling.  
Bone modeling is the process where bone resorption and bone formation work 
independently to “customize” the shape of bones [2].  Modeling occurs during childhood 
allowing bones to sculpt themselves by removing or adding bone to form the optimal 
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geometry that will support loads placed on the bone [2].  Bone modeling decreases once 
the skeleton has matured while remodeling continues throughout an individual’s lifetime.  
Bone remodeling is the process where bone resorption and bone formation cells 
work together to form a cellular unit called a basic multicellular unit (BMU) to remove 
old bone and replace it with newly formed bone [2].  Unlike modeling, remodeling 
typically does not affect the shape or size of the bone, but instead repairs fatigue damage 
before it leads to fracture [2].  Because remodeling occurs throughout an individual’s 
lifetime, bone remodeling greatly affects the mechanical properties of bone.  
Bone remodeling can be initiated by a number of factors including mechanical 
stimulus, damage, and chemical factors such as hormone and calcium levels [2].  Bone is 
designed to maintain homeostasis; so, when strain levels fall below normal, bone is in a 
state of disuse and bone remodeling is activated in order for BMUs to remove unneeded 
bone. Similarly, in an overload state, or when there is an increase in loading, remodeling 
is activated to deposit more bone to maintain the integrity of the bone. Remodeling can 
also be initiated by cyclic loading which can cause fatigue damage in the form of 
microcracks that may eventually lead to bone fractures (Figure 5).  
 
 
Figure 5. Histological section of a microcrack found in cortical bone. Microdamage 
accumulation can be initiated by cyclic loading which may lead to fractures if not repaired 
by bone remodeling [48]. 
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If the damage is allowed to accumulate, bone strength is compromised and fracture risk is 
increased; so, bone remodeling is crucial in order to remove damage and prevent bone 
failure.  Bone lining cells have also been thought to trigger remodeling by sensing 
increases in stress and strain and relaying that information to osteocytes.  The osteocytes 
then recruit osteoclasts to resorb bone at that specific location [2].  Osteocytes can also 
initiate remodeling by releasing chemical signals that activate remodeling after 
undergoing apoptosis when sensing changes in stress [2].  The process of bone 
remodeling can be divided into six stages (Figure 6): 
Activation Stage. The first stage is called the activation stage and is initiated by a 
chemical or mechanical stimulus that triggers progenitor cells to differentiate into 
osteoclasts [2].  The osteoclasts are then recruited to a specific area to form the resorption 
area of the BMU.  
Resorption Stage. Once the osteoclasts are formed, the cells resorb bone by secreting 
enzymes and hydrogen ions into the resorption space.  Resorption occurs at a rate of 
about 40 µm a day for about 3 weeks in humans [2].  Bone is resorbed in the form of a 
ditch in trabecular bone and as resorption cavities or a tunnel in cortical bone [2].  
Reversal Stage. The reversal stage is where the transition between osteoclasts and 
osteoblasts take place. Once the osteoclasts have created a cavity for bone formation, the 
cells undergo apoptosis while the osteoblasts form along the borders of the resorption 
cavities. The reversal line is often called the cement line because it separates where bone 
formation begins and marks the boundary of the newly forming osteons from the older 
bone [2].  
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Formation Stage. Bone formation occurs in two stages: matrix formation followed by 
mineralization.  Osteoblasts deposit an osteoid layer along the outer edge of the 
resorption cavity.  A canal is left in the center of the refilled cavity for the Haversian 
canal.  This is essential to provide the osteoblasts and osteoclasts with nutrients and waste 
removal.  The blood supply also transports calcium and phosphate ions into the bone 
matrix to nourish the osteocytes [2].  Bone formation takes much longer than resorption, 
lasting about 3 months.  
Mineralization Stage. The second phase of formation is the mineralization stage.  During 
this stage, the unmineralized osteoid tissue becomes mineralized with hydroxyapetite [2]. 
The mineralization stage happens in two parts: primary mineralization occurs within a 
couple days and mineralizes about 60% of the osteoid [2], and secondary mineralization 
can last up to one year to mineralize the remainder of the osteiod tissue [16].  This delay 
in mineralization can cause osteons to exhibit different mechanical properties [2].  
Quiescence Stage. The final stage of bone remodeling occurs after resorption and 
formation have completed.  The BMUs begin to split apart, prompting osteoclasts to 
disappear and osteoblasts to become osteocytes, bone lining cells, or disappear entirely 
[2].  
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Figure 6.  Bone remodeling stages. (1)Activation is initiated by some stimulus which recruits 
osteoclasts. (2) Osteoclasts resorb old bone in the resorption stage. (3)The reversal stage is a 
transition period where resorption ends and formation begins. (4)Osteoblasts form new 
bone matrix in the formation stage. (5) Osteiod tissue becomes mineralized. (6) Bone 
formation and resorption are complete and osteoblasts become bone lining cells. [3] 
 
 
 
1.5 Osteoporosis 
 
Osteoporosis is a common skeletal disorder that is characterized by an imbalance 
in bone remodeling in which the rate of bone resorption exceeds the rate of bone 
formation.  When more bone is being removed than is being replaced, there is an increase 
in bone porosity and a loss of bone mass leading to bone fragility and an increase in 
fracture risk (Figure 7).  Some of the common causes of osteoporosis are: immobility, 
1 
2 
3 
4 
5 
6 
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malnutrition, age, and a decrease in estrogen which is associated with an increase in 
osteoclast activity [1].  Individuals who do not exercise and are inactive can increase their 
chances of developing osteoporosis because bone disuse can lead to bone loss.  Lack of 
nutrients such as calcium and vitamins can also affect the health of bone because they are 
essential to form the bone matrix [1].  The risk of osteoporosis is further increased with 
age for both men and women; however, post menopausal women are two and half times 
more likely to develop signs of osteoporosis as a result of the decrease in estrogen [5].  
 
  
 
 
Figure 7. The comparison between normal and osteoporotic bone demonstrates an 
increase in porosity in the diseased bone as well as a thinning of the bone tissue [6]. 
 
 
 
The National Osteoporosis Foundation has estimated that the number of people 
with or at risk for osteoporosis will exceed 52 million by the year 2010 [7].  Because 
osteoporosis can greatly affect the individual’s quality of life, prevention and 
management of the disease is important.  Treatments for osteoporosis hope to reduce 
bone loss and increase bone formation.  Daily doses of calcium and vitamin D can 
prevent bones from becoming weaker and reduce the risk of osteoporosis.  Regular 
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exercise can also stimulate bone remodeling and help build stronger bones by reducing 
bone loss and increasing bone mass.  Drug treatments are another effective way to treat 
and prevent osteoporosis.  
 
 
1.6 Bisphosphonates 
 
Antiresorptive drugs reduce bone remodeling in hopes of increasing bone 
mineralization and produce a more stable structure [8].  Bisphosphonates are a class of 
antiresorptive drugs that increase bone mass and reduce fracture risk by suppressing 
osteoclastic activity by inhibiting the activation of BMUs [33, 35, 36, 37] and reducing 
the size of bone resorption sites [33, 38, 39, 42].  All bisphosphonates share a common 
backbone structure composed of two phosphate groups bound by a carbon (Figure 8) 
[11].  The phosphate groups are negatively charged, giving bisphosphonates a strong 
affinity to calcium and limiting any side effects of the drug on non skeletal tissues [12].  
Bisphosphonates also consists of a R1 and R2 side chain each with their own unique 
structure that determines the effectiveness of the drug.  The R1 side group controls the 
pharmacokinetics or absorption ability of the drug while the R2 side chain determines the 
mode of action and the strength of the drug [11]. 
 
  
 
Figure 8. Basic chemical structure of bisphosphonates [13].  
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There are two types of bisphosphonates: nitrogenous and non-nitrogenous 
bisphosphonates.  First generation bisphosphonate do not contain a nitrogen group so are 
referred to as non-nitrogenous.  These drugs are less potent and do not target bone as well 
as nitrogenous bisphosphonates [12].  Second generation bisphosphonates have a 
hydroxyl R1 side chain and a nitrogen group on the R2 side chain (Table 1).  The R1 
hydroxyl group enhances the drugs bone binding affinity to hydroxyapatite while the R2 
side group determines the anti-resorptive properties of the drug [11].  The different 
nitrogen based bisphosphonates vary only at the R2 group giving each drug its own 
pharmacological properties [12]. 
The structural variations between bisphosphonates explain their differences in 
binding affinity and anti-resorptive ability [11].  The potency of each bisphosphonate is 
therefore related to these factors which plays an integral role on the biological effects of 
the drug.  These differences are related to the ability of the drug to attach to bone, its 
duration of effect, and the ability for the drug to inhibit farnesyl disphosphate synthase 
(FPP synthase) for nitrogenous based bisphosphonates [11].  This mechanism of action 
will be explored in more detail in a subsequent section.  In vivo and in vitro studies on 
rats have shown a steady increase in the potency of bisphosphonates with each 
succeeding generation of drug [11].  More recent bisphosphonates like risedronate, 
ibandronate, alendronate, and zolendronate were more potent in comparison to older 
bisphosphonates like etidronate (Figure 9) [11].  The results of the study align with the 
fact that recent bisphosphonates contain a nitrogen group on their R2 side chain which 
inhibits FPP and attributes to a higher potency factor [11].  Although nitrogenous 
bisphosphonates (nBPs) have a higher potency factor, certain nBPs like risedronate do 
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not have as strong a binding affinity to bone as others [11]; therefore, the type of 
bisphosphonate administered and the dosing schedule is important when determining how 
well the drug will be diffused in the bone and its resorption ability [11].  The effects of 
bisphosphonates on bone also differ in their ability to reduce bone remodeling, decrease 
fracture risk, and increase mineralization depending on the drugs structure, potency, 
treatment dose, length of treatment, and the bone’s initial remodeling rate [40].  Higher 
doses of bisphosphonate can produce increased reductions in activation frequency of up 
to 93% [33]; however, this can also result in significantly higher levels of microdamage.  
Therefore, determining an optimal dosage and potency for different sites are important 
when treating patients.  
 
 
 
Table 1. Basic chemical structure of bisphosphonates. All nBPs have a hydroxyl R1 side 
chain and differ only at the R2 side chain [14]. 
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Figure 9. Binding affinity of common bisphosphonates.  Zolendronate, Alendronate, 
Ibandronate, and Risedronate are nBPs and Etidronate and Clodronate are non-nBPs [11].  
 
 
 
Alendronate is one of the most commonly prescribed bisphosphonates used for 
the treatment and prevention of osteoporosis.  It was approved for the treatment of 
osteoporosis by the FDA in 2005 as a second generation nitrogen based bisphosphonate 
manufactured by Merck & Co. under the commercial name Fosamax.  
Although the exact mechanisms of action for bisphosphonates are not entirely 
understood, it is clear that bisphosphonates inhibit osteoclasts and reduce bone turnover. 
The effects of the drug can be categorized into three levels: tissue, cellular, and 
molecular. 
Tissue level. At the tissue level, bone remodeling is reduced due to a suppression in bone 
resorption [15].  Because resorption and formation are coupled, by decreasing bone 
turnover rate, the newly formed bone and older bone will have more time to complete 
mineralization therefore increasing the mineral content of bone [16].  Bisphosphonates 
increase bone mass by reducing remodeling space which reduces porous areas and creates 
a positive bone balance where resorption does not exceed formation [10]. 
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Cellular level. At a cellular level, bisphosphonates target osteoclasts and areas of bone 
resorption.  Osteoclasts bind to the bone surface as usual, but when bisphosphonates are 
taken up by the osteoclasts, the cytoskeleton of the cell is disrupted, causing the ruffled 
border to disappear.  Bone resorption declines due to the lack of a ruffled border which 
plays an integral role in the osteoclasts ability to resorb bone [10].  
Molecular Level.  At the molecular level, nitrogen based bisphosphonates inhibit farnesyl 
disphosphate synthase (FPP synthase) which is an enzyme in the mevalonate pathway 
(Figure 10) [12].  FPP synthase triggers isoprenylation, a process that activates small 
GTPases such as Rab, Rac, Ras, Rho [12].  GTPase is a family of enzymes that signals 
proteins that regulate many properties that are important for osteoclast functions 
involving vesicular trafficking, cytoskeletal arrangement, and membrane ruffling [12]. 
When the ruffled border of the osteoclast is interrupted, the degradation of the collagen 
matrix is hindered and the osteoclast’s ability to resorb bone is inhibited [12].  High 
concentration of bisphosphonate can also induce apoptosis and inhibit osteoclast 
differentiation [12].  
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Figure 10. Comparison of normal osteoclast function and the effects of nBPs on osteoclasts 
[14]. 
 
 
Many experimental studies have been performed that demonstrate the effects of 
alendronate on bone.  Bone strength is one of the determinants of the effects of a 
bisphosphonate on bone quality.  The strength of bone is determined by a number of 
factors including the bone volume, micro-architecture, and degree of mineralization of 
bone [43].  Osteoporosis results in bone loss, which causes a weakening of the micro-
architecture of bone and an increase in the activation frequency of bone remodeling 
which effectively reduces the degree of mineralization [43].  In order to offset these 
harmful effects, alendronate can be given to reduce the bone turnover rate.   
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A study by Mashiba et al. [33] showed that the activation frequency for bone 
remodeling is suppressed after 1 year of alendronate treatment.  The decrease in bone 
remodeling caused microdamage accumulation to increase as well as caused a decrease in 
the toughness, or the ability to absorb energy, of bone.  Histological analysis on the dog 
ribs also showed a reduction in resorption cavity size with the use of bisphosphonates 
[33, 36].  
In addition to reducing activation frequency and reducing resorption cavity area, 1 
year bisphosphonate studies have also been found to increase bone mass.  The underlying 
effect of bisphosphonate treatment is to reduce bone resorption which in effect reduces 
bone formation and reduces the overall bone turnover rate.  Within a few month of 
treatment, a positive bone balance is obtained and primary mineralization is increased 
[41].  This reduction in bone turnover will then decrease the resorption size and allow for 
secondary mineralization, both which further increase the bone density and reduce 
fracture risk [41].  The effects of increasing bone mass should then increase bone strength 
and improve the mechanical properties of bone [41, 44].   
Using alendronate doses equivalent to those used to treat post menopausal 
osteoporosis, 1 year beagle vertebral studies performed by Allen et al.’s group [17] 
demonstrated a reduction in the activation frequency of bone remodeling, an increase in 
microdamage, stiffness,  bone volume, and mineralization with no significant effect on 
the mechanical properties of bone [17].  3 year rib studies, also performed by Allen et 
al.’s group [18], showed similar results to 1 year studies; but, this study showed that 
damage accumulation was not significantly higher compared to the 1 year studies [18].  
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Two and three year studies have also been performed to confirm a reduction in 
activation frequency and an increase in bone mineral density [36, 42, 43] when 
alendronate was administered.  These results are most likely caused by the increase in 
mineralization [36, 43].  The results also show a reduction in fracture rate which has been 
linked to improved bone strength [36, 43].   Although many experiments have been 
performed that demonstrate the effects of alendronate on bone, the short time frames of 
these studies necessitates additional research to determine the long term effects of 
bisphosphonates.  
Bisphosphonates are used to manage the rate of bone remodeling in order to 
reduce the risk of fractures; however, when bone remodeling is reduced, microdamage 
removal is also reduced, making the bone weaker which in the long run, may increase 
fracture risk and cause bone to be more brittle [10].  Although bisphosphonates suppress 
bone remodeling and the resorption of bone in order to increase tissue mineralization and 
bone volume [17], they have also been associated with the impairment of microdamage 
removal in canines which has been shown to lead to weaker bones [10].  An increase in 
mineralization along with the increase in microdamage make bone less resistant to crack 
propagation and more susceptible to fractures [10].  Although several studies have 
confirmed the increase in microdamage accumulation following bisphosphonate 
treatment [9,10,17,18] , three year results have shown similar levels of microdamage as 
one year treatment results which suggests that microdamage accumulation is limited 
beyond the initial increase after one year of treatment [18].   
It is important to determine the relationship between bone remodeling and 
microdamage accumulation in order to understand the long term effects of 
  
 
22 
bisphosphonates. The lasting effects of bisphosphonates are still unclear due to the 
difficulty in obtaining long term data; therefore, developing mathematical models based 
on the results and relationships from short term studies can be a useful method in 
predicting the effects of the drug.  The purpose of this study is to simulate the effects of 
alendronate on dog ribs using a computational model based on experimental data results.  
The mathematical model was developed by simulating results obtained from 
experimental control data, and then the effects of alendronate treatment on cortical bone 
remodeling and microdamage in canine ribs were examined by modifying the simulation 
in an attempt to match one and three year experimental data.  
 
 
1.7 Previous Models 
 
Understanding the variables related to bone remodeling will help to develop a 
model that can determine the long term effects of alendronate on the mechanical 
properties of bone.  Because bone is a dynamic structure, bone remodeling algorithms 
must incorporate the effects of bone adaptation to both mechanical and biological stimuli 
which can be triggered by mechanical loading and fatigue microdamage [19]. 
Computational models have previously been developed to test hypotheses about bone’s 
adaptability to both biological and mechanical stimuli.  Carter et al. [20] and Huiskes et 
al. [21] introduced the first finite element models to simulate the mechanical adaptability 
of bone (Figure 11).  Both approaches are equivalent but used different coefficients for 
the daily mechanical stimulus [2].  In these models a daily mechanical stimulus based on 
stress [20] or strain [21] was used alongside an error function that tracked the change in 
daily mechanical stimulus in order to calculate changes in the elastic modulus over time. 
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The error function is defined as the difference between the actual stress or strain stimulus 
and the attractor state stimulus or the equilibrium value and is the “driving force for bone 
remodeling” [45].  The new modulus was obtained by multiplying the changes in the 
apparent density of the bone by a constant which would be used to calculate the new 
daily mechanical stimulus for the next time step [2].   This process was repeated in an 
iterative fashion for the desired period of time.  Although both models were able to 
simulate the mechanical adaptability of bone, neither included a cellular response. 
 
 
 
Figure 11. Simplified diagram of Carter et al. and Huiskes et al.’s bone adaptability 
model. 
 
 
Hazelwood et al. [19] extended these models to include a more complete 
representation of bone remodeling by incorporating bone adaptability in response to 
mechanical and biological stimuli during a state of disuse (low strain) and overload (high 
strain).  Because bone remodeling is activated during both a state of disuse and in a state 
of overload, porosity and elastic modulus were modified for each time step in order to 
account for the change in loading (Figure 12).  In the model, varying loads were placed 
Net apposition and 
resorption rate of bone 
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on a representative bone volume to simulate different loading conditions that would 
mimic the bone under disuse and overload which was determined by the strain [19].  
During disuse (low strain), activation frequency increases, causing the bone porosity to 
increase due to an elevated resorption cavity area [19].  The elastic modulus is 
determined using a nonlinear relationship with porosity which is changed for each time 
step in the model [19].  During overload (high strain), bone is subject to increased 
damage formation due to the high loading rate.  The damage removal rate has previously 
been modeled by Martin [22].  Similar to the pathway for disuse, the increase in damage 
triggers an increase in activation frequency which in effect adjusts the porosity of the 
bone with each time step of the model.  
 
 
 
Figure 12. Schematic of bone remodeling algorithm by Hazelwood et al.[19]. 
 
 
In order to simulate the effects of bisphosphonate on bone, clinical data was used 
to match the results for a mathematical model.  Bisphosphonate treatment will reduce the 
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bone turnover rate and create a positive bone balance which allows bone mass to increase 
[16].  The decrease in bone turnover will also reduce the remodeling space area and allow 
bone more time to mineralize which will cause bone mineral density (BMD) to increase 
[16].  Hernandez et al. [16] developed a model to compare two methods to simulate the 
effects of alendronate treatment on BMD (Figure 13).  The bone balance method was first 
introduced by Heaney et al. [23] who modeled alendronate treatment as a decrease in  
bone turnover, an increase in bone balance, and a constant bone mineralization.  The 
mineralization method on the other hand, modeled alendronate as a constant bone balance 
and a change in both bone turnover and bone mineralization [16].  The results of both 
methods were able to predict increases in BMD based on clinical studies; however, the 
bone balance method attributed the majority of the BMD changes to the bone balance 
while only accounting for a 6 month secondary mineralization period.  Because the time 
period for secondary mineralization can occur for years, the mineralization method, 
which incorporated a longer secondary mineralization period, was a better indicator of 
the long term changes in BMD [16].  Although both Heaney and Hernandez’s model 
were able to calculate changes in BMD, both failed to include the effects of a mechanical 
stimulus on bone’s adaptability.  
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Figure 13. Schematic of the computational model for bone remodeling by Hernandez et al. 
[16]. The model presents the progression of BMU remodeling activity in a representative 
volume of trabecular bone over time.  The number of active BMUs is dependent on the 
number of newly formed BMUs and the number of terminating BMUs.  As the BMUs 
advance through the remodeling cycle, they undergo resorption, reversal, mineralization, 
and a formation period, all which are tracked by the model at each time point.  The sum of 
all BMUs that are resorbing and forming and the resorption and formation rates are then 
used to calculate the bone volume that is being resorbed or formed at each time step.  The 
volume formed and resorbed is then subtracted to obtain the bone volume fraction which 
determines the number of new BMUs available for the next time step [16]. 
 
 
 
 
By incorporating Hazelwood et al.’s [19] mechanical and cellular responses with 
the previously described bisphosphonate models, Nyman et al. [10] developed a 
computational model to simulate the long term effects of bisphosphonate on bone mass 
and microdamage accumulation in humans by modeling the effects of BMU activation 
frequency suppression and BMU resorption reduction under a state of disuse, 
microdamage, and estrogen deficiency [10].  The computational model was developed for 
trabecular bone remodeling to examine the conditions in which bone mass would increase 
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without causing microdamage to linearly increase over time.  The results of the model 
predicted an increase in bone volume with limited microdamage accumulation as long as 
activation frequency was not completely suppressed [10].  The results were simulated by 
varying both the potency of the drug and the bone balance in order to determine the 
optimal amount of activation frequency suppression needed to increase bone volume.  
The model predicted that microdamage accumulation was limited when activation 
frequency was incompletely suppressed (Figure 14).  In previous models that did not 
include a disuse response, activation frequency suppression caused an increase in 
microdamage and resulted in an unlimited bone gain due to the decrease in damage 
removal and resorption area size respectively [10].  However, by including the disuse 
response to this model, the increase in bone volume will in effect lower the strain which 
triggers an increase in activation frequency due to the disuse response and decrease 
damage formation [10].  The results of the model show that microdamage does not 
continue to accumulate and the increase in bone mass will plateau over time [10].  
Nyman et al.’s [10] model for humans is used as the foundation of the computational 
model developed here for canine dog ribs, and is more closely examined in the following 
chapter. 
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Figure 14.  Microdamage accumulation predicted by Nyman et al. [10].  
Microdamage was expected to increase linearly over time when the activation frequency 
was completely suppressed; however, if remodeling was incompletely suppressed, 
microdamage accumulation was found to increase initially then reach a new equilibrium 
over time [10].  
 
 
1.8 Study Goals 
 
The objective of this study is to develop a computational model that can simulate 
the effects of alendronate treatment on canine rib remodeling and microdamage that have 
been observed in experiments.  Although several studies have confirmed an initial 
increase in microdamage accumulation following bisphosphonate treatment, 3 year 
treatment results have shown similar levels of microdamage as 1 year treatment results 
which suggests that microdamage accumulation is limited beyond the initial increase at 1 
year of treatment [18].  The long term effects of bisphosphonates are still unclear due to 
the difficultly in obtaining long term data; therefore, developing a mathematical model 
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based on experimental data and relationships from short term studies can be a useful 
method in predicting the effects of the drug.  
The purpose of this study is to modify previous mathematical models to match the 
control, 1, and 3 year experimental data results from canine studies.  The experimental 
data were obtained from the Indiana University School of Medicine where the dogs were 
treated with a vehicle or one of two dosages of alendronate.  After 1 and 3 years, the dog 
ribs were excised for analysis and quantified using standard histomorphometric 
techniques.  The mathematical model was developed by simulating results obtained from 
the experimental control data, and then the effects of alendronate on cortical bone 
remodeling and microdamage in canine ribs were examined by modifying the simulation 
in an attempt to match the 1 and 3 year experimental data.  Nyman et al.’s computational 
model for trabecular bone adaptation based on microdamage and mechanical loading [10] 
was modified in this study to simulate remodeling and bisphosphonate treatment in a 
representative volume of cortical bone in the canine rib. The model incorporates 
biological factors and mechanical influences to simulate the remodeling process and is 
altered in this study to create a program that would match the experimental data for 
remodeling in the ribs of the 1 year control animals. Using this simulation as the baseline 
condition, the effects of ALN were modeled by suppressing activation frequency and 
reducing the resorption area. The changes in BV/TV, damage accumulation, and Ac.f 
were then simulated for 1 and 3 years and compared to experimental results.  Unlike 
Nyman et al.’s model which involved numerous of assumptions as to which remodeling 
parameters would be used for human trabecular bone, the present model uses 
experimental data for cortical canine rib bone to simulate and validate the model. 
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This simulation will help in developing improved methods of predicting 
bisphosphonate treatment on bone as well as determine if the long term effects of 
bisphosphonate usage will indeed reduce fracture risk.  The understanding of the effects 
of bisphosphonate treatment on dog ribs can also aid in developing better models to 
simulate the effects of bisphosphonate treatment in humans. 
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CHAPTER 2: MATERIALS AND METHODS 
 
 
 
2.1 Experimental Design  
 
Before developing the model, histomorphometric data was obtained from 
experimental results and samples given by the Indiana University School of Medicine in 
order to validate the results obtained from the model.  All experimental procedures were 
approved by the Indiana University School of Medicine Animal Care and Use Committee 
prior to beginning the study.   
 
2.1.1 One Year Canine Experimental Methods 
   
For the 1 year animal study, seventy-two skeletally mature female beagles (1-2 
years old) obtained from Marshall Farms (North Rose, NY) were treated daily for 1 year 
with oral doses of vehicle (saline control, 1ml/kg/day), risendronate sodium (RIS, 0.05, 
0.10, 0.50 mg/kg/day; Proctor & Gamble Pharmaceuticals, Norwich, NY), alendronate 
(ALN, 0.10,  0.20, or 1.00 mg/kg/day; Merck, RAHWAY, NJ), or raloxifene (0.50 
mg/kg/day; Lilly Research Labs, Indianapolis, IN) [30]. The middle treatment doses 
(RIS0.10 and ALN0.20) were determined based on clinically relevant doses used to treat 
postmenopausal osteoporosis, the higher treatment doses (RIS0.5, ALN1.0) corresponds 
to 5x the clinical dose used to treat osteoporosis, and the lower doses (RIS0.05, 
ALN0.10, raloxifene 0.50) corresponds to approximately half these clinical treatment 
doses [30].  The recommended dose of alendronate for the treatment of osteoporosis is a 
70 mg tablet per week [49] which equals 0.2 mg/kg/day in a 50 kg human. Although 
  
 
32 
several drugs were compared, for the purpose of the current study, alendronate at 0.2 and 
1.0mg/kg/day will be the only drug discussed from hereon since it was the only drug used 
in the 3 year study.  Prior to treatment, x-rays of all dogs were taken to ensure skeletal 
maturity (closed proximal tibia and lumbar vertebra growth plates) [30].  Following a 2 
week acclimatization period, the dogs were divided into groups of 12 based on their body 
weight [30].  The drug treatments were administered orally with a syringe for the vehicle 
saline solution and by dissolving alendronate into saline each morning after an overnight 
fast and two hours before feeding [30].  After 1 year of treatment, the animals were 
intravenously injected with calcein (0.20 ml/kg) using a 2-12-2-5 or 2-5-2-5 labeling 
schedule then euthanized by intravenously administrating sodium pentobarbital (0.22 
mg/kg) [30].  The discrepancy in labeling was due to a scheduling error [30].  After 
necropsy, the right ninth rib was removed and placed in 10% neutral buffered formalin 
for 72 hours and then moved to a 70% ethanol solution for histological assessments [30].   
 The bone samples were embedded with methyl methacrylate (MMA; Aldrich, 
Milwaukee, WI) and cut transversely into sections (80-100µm) using a diamond wire saw 
(Histosaw; Delaware Diamond Knieves, Wilmington, DE) [30].   One cross sectional 
bone sample per animal was used for the measurements using a semiautomatic system 
(Bioquant OSTEO 7.20.10; Bioquant Image Analysis, Nashville, TN) attached to a 
microscope equipped with an UV light source (Nikon Optiphot 2; Nikon, Tokyo, Japan) 
[30].  Analysis for the 1 year study was performed by the Indiana University School of 
Medicine and the results are listed below (Table 2). 
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Table 2. Histomorphometric data from 1 year canine rib studies obtained from the Indiana 
University School of Medicine 
 
Vehicle 
(1ml/kg/day) 
Alendronate 
(0.20 mg/kg/day) 
Alendronate 
(1.00 mg/kg/day) Source 
Formation Period, days 66.14 ± 55.12* -- -- [30] 
Activation Frequency, 
#/mm2/day 0.0384 ± 0.0290
*
 0.0361 ± 0.0322* 0.0202 ± 0.0134* [30] 
Microdamage 
(mm/mm2) 0.0169 ± 0.0189
*
 0.0326 ± 0.0339* 0.0332 ± 0.0393* [30] 
* Unpublished data from specimens in [30]. 
 
 
 
  
2.1.2 Three Year Canine Experimental Methods 
 
For the 3 year study, Indiana University School of Medicine performed a canine 
study on thirty-six skeletally mature female beagles (1-2 years old, n=36) [24].  X-rays of 
the dogs were acquired to confirm skeletal maturity (closed proximal tibia and lumbar 
vertebra growth plates) [24].  Following a 2 week acclimatization period, the animals 
were divided into 3 groups (n = 12/group) each treated daily for 3 years with oral doses 
of vehicle (saline control, 1ml/kg/day) or alendronate (ALN, 0.2 or 1.00 mg/kg/day; 
Merck and Co.) [24].  The dosing for the alendronate treatment corresponds to doses used 
to treat postmenopausal osteoporosis (ALN0.2) and 5 times that amount used to treat 
Paget’s disease (ALN1.0) [24].  The drug treatments were administered orally with a 
syringe for the vehicle saline solution and by dissolving alendronate into saline each 
morning after an overnight fast and two hours before feeding [24].  All 36 animals 
completed the 3-year study with no serious complications [24].  Following 3 years of 
treatment, the animals were injected with calcien (5 mg/kg as a 3% solution, IV) on a 2-
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12-2-5 labeling schedule prior to necropsy [24].  The animals were euthanized by 
intravenous administration of sodium pentobarbital (0.22 mg/kg Beuthanasia-D Special) 
and the mid section of the ninth rib was removed and preserved in 70% ethanol or 10% 
neutral buffered formalin for microdamage and histomorphometric evaluation, 
respectively [18].  In addition, the left eleventh rib was maintained in a saline soaked 
gauze and frozen to -20 ºC for further measurements [18].   From these experiments, the 
following results were obtained from the Indiana University School of Medicine and used 
for the model (Table 3).  
 
 
Table 3. Histomorphometric data from 3 year canine rib studies obtained from the Indiana 
University School of Medicine  
 
Vehicle 
(1ml/kg/day) 
Alendronate (0.20 
mg/kg/day) 
Alendronate 1.00 
mg/kg/day) Source 
Activation Frequency, 
#/mm2/day 0.00902 ± 0.00780
*
 0.00153 ± 0.00215* 0.00521 ± 0.00792* [24] 
Microdamage 
(mm/mm2) 0.0248 ± 0.0274 0.0449 ± 0.0273 0.0408 ± 0.0216 [24] 
Elastic Modulus 
(MPa) 5601 ± 318 5524 ± 320 5678 ± 407 [24] 
* Unpublished data from specimens in [24]. 
 
 
 
2.2 Sample Preparation 
 
For the histomorphometric analysis in the previous studies performed at the 
Indiana University School of Medicine, the bone samples were stained en bloc with 1% 
basic fuschin and embedded undecalcified in methyl methacrylate [24].  Thirty-six bone 
samples from the 3 year canine rib study were obtained from the Indiana University 
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School of Medicine and used to obtain further data described below.  Using the facilities 
at Cal Poly, two transverse sections were cut from each of the thirty-six bone samples 
using a high precision bone saw (Isomet 1000; Buehler Ltd., Lake Bluff, IL), then sanded 
to a thickness of around 100 micrometers using 400 grit sandpaper and mounted onto 
microscope slides (Eukitt Mounting Medium; Electron Microscopy Sciences, 
Hatfield,PA). 
 
 
2.3 Histomorphometric Analysis 
 
For this study, the 1 and 3 year experimental data for activation frequency (Ac.f) 
and microdamage for the control and both doses of alendronate were obtained from the 
Indiana University School of Medicine (Table 2 and 3).  Since the 3 year bone samples 
were also provided for analysis at Cal Poly, histomorphometric measurements to 
determine the bone volume fraction (BV/TV) were performed for the control and both 
dosages of alendronate to be used as a reference to develop the computer model.  All 
measurements were performed blinded.  After preparing the samples for analysis, a 
semiautomatic analysis system (Bioquant Image Analysis, Nashville, TN) attached to a 
microscope equipped with an UV light source (Nikon, Tokyo, Japan) was used to 
calculate the bone volume fraction.   For each of the thirty-six bone samples, two 
transverse sections were cut per bone sample (72 total) and used to measure the porous 
areas of the cortical portion of the bone including the resorption spaces, Volkmann’s 
canals, and Haversian canals (Figure 15).   The bone’s microstructure was analyzed using 
Bioquant by manually circling the porous spaces in multiple sections of the entire cortical 
bone sample.  The porous areas for each section were then added together and divided by 
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the total cross section of the cortical bone area to obtain the porosity of the bone sample.  
Because two slides were made per bone sample the porosity value for each slide was 
averaged to get one value.  The BV/TV was then calculated as 1 minus the porosity.  
 
 
 
Figure 15.  Porous areas in cortical bone under fluorescent microscope. 
 
 
2.4 Remodeling Simulation 
 
Mechanical Loading.  The model simulates adaptive remodeling in a 1 cm3 representative 
volume of cortical rib bone under uniaxial cyclic loading.  Assuming a linear relationship 
between the apparent density (ρ) and the porosity (p), the elastic modulus (E) of the 
representative volume was assumed to be proportional to the bone volume fraction 
(BV/TV) in the following relationship, 
 
( )aTVBVEE /0 ×= ,        (1) 
 
 
where E0 = 6634.24, a = 5.4994, and BV/TV = (1 – p) for cortical rib bone.  These values 
were estimated given the available data for the elastic modulus (Table 3) and the 
100µm 
Haversian Canals 
Volkmann Canal 
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measured values for the bone volume fraction (Table 5) from the 3 year experimental 
study [24].   The elastic modulus and bone volume fraction values were input into Eq.1 
for each treatment group (CON, ALN0.2, ALN1.0) to obtain three equations, and 
linearized by applying the natural log to both sides.  The general formula used was: 
0ln)ln(ln ETV
BV
aE += ,        (2) 
 
which follows the equation y = mx + b, or in this case, ln(y) = mln(x) + lnb where “m” is 
the slope and corresponds with the “a” in Eq. 2 and “lnb” is the y-intercept which 
corresponds to the lnE0.  To find the slope and y-intercept, ln(BV/TV) versus lnE was 
plotted out for each treatment group.   The slope of the best fit line was adjusted, within 
range of the standard deviations, to create a positive slope of a = 5.4994 (Figure 16).  The 
elastic modulus was calculated by taking the e of the y-intercept to obtain E0 = 6634.24. 
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Figure 16.  Proposed relationship between the bone volume fraction and the 
elastic modulus. 
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As described in the previous models, the porosity and elastic modulus adapt throughout 
the simulation based on the effects of disuse and damage on bone remodeling (Figure 
12).  Although porosity is used throughout the simulation, the porosity is changed to bone 
volume fraction (BV/TV = 1 – porosity) for the analysis.  The disuse and damage 
response are modeled using the strain and the loading rate of the representative volume.  
Using Hooke’s Law, the peak strain (ε) was calculated as 
 
,/ Eσε =
         (3) 
 
 
and the mechanical stimulus or loading potential was defined as 
 
 
,1 qrl ε×=Φ
         (4) 
 
 
where rl1 is the loading frequency in cycles per day (cpd) and q is a constant that adjusts 
the peak strain and loading frequency to the loading potential [10].  
 
Porosity Transformation.  The change in porosity is associated with the bone resorbing 
rate (QR) and bone refilling rate (QF) for each BMU, and the number of resorbing (NR) 
and refilling BMUs (NF) per unit area. The resorption rate, 
 
RRR TAQ /=          (5) 
 
 
and the refilling rate,  
 
 
FFF TAQ /=          (6) 
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were assumed to be linearly related with time where A, TR, and TF  are the cross-sectional 
area of each BMU, the resorption period, and the refilling period, respectively [26,27].  
The number of resorbing BMUs (NR) and the number of refilling BMUs (NF) was found 
by integrating the BMU activation frequency over the present time (t), resorption (TR), 
reversal (TV) and refilling (TF) time periods accordingly,  
( )∫
−
=
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R
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        (7) 
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to obtain the change in porosity: 
 
 
FFRR NQNQp −=& .        (9) 
 
 
TR is the time interval beginning from the instance resorption begins to the moment the 
osteoclasts stop resorbing.  TV is the inactive transition period between osteoclastic to 
osteoblastic activity, and TF is the interval in which osteblasts from the BMU form bone 
[19].   
 
 
BMU Activation Frequency.  The activation frequency is the number of new BMUs 
created per unit area per time (BMUs/mm2/day).  BMU activation frequency was 
assumed to be a function of both damage and disuse and the specific surface area (SA) in 
the equation: 
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( ) .)()( Adamagedisuse SAcfAcfAcf +=        (10) 
 
 
The specific surface area is the amount of surface area available for new BMUs, which is 
also defined as the bone surface per total sectional area (BS/TA). In order to ensure that 
the area taken up by the new BMUs did not exceed the available surface area, SA was 
divided by the maximum specific surface area (SAmax) to obtain values between 0 and 1 in 
a relationship between porosity and surface area,  
 
( ) ,/8.281011349.931.32 max5432 AA SpppppSTS
BA
+−+−==
  (11) 
 
which was developed by Martin [28].  The activation frequency was then normalized 
using SA.  The activation frequency for microdamage and disuse was calculated by fitting 
hypothetical dose response curves for activation in response to disuse and damage [10].  
The disuse response was defined as a mechanical stimulus value Φ below the equilibrium 
mechanical stimulus value Φ0.  During a state of disuse (Φ< Φ0), the refilling rate (QF) is 
reduced;  so, the area of bone formation was also reduced by adjusting the area of 
formation by A[0.5+0.5(Φ/ Φ0)] to account for the reduction in refilling rate on the bone 
surface [19].  The relationship between the activation frequency and the disuse and 
damage was modeled assuming a sigmoidal relationship [19] between mechanical 
stimulus and Acf(disuse) 
 
)(
(max)
)( 1 cb kkdisuse e
Acf
Acf
−Φ+
=
        for Φ < Φ0.     (12) 
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and damage and Acf(damage), 
 
 
 
   
 
( )( )
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rkdamage eAcfAcfAcf
AcfAcf
Acf −
−+
= ,    (13) 
 
 
 
where D0  corresponds to the initial equilibrium damage and Acf(max) was the maximum 
allowable activation frequency which was intended to be much higher than the highest 
average activation frequency for human cortical bone assuming that the value would not 
reach this upper limit [19,29].  The sigmoidal curves were found by matching the 
responses found in pharmacological applications [19].  The constants k were determined 
by fitting the curves based on a range of clinical data [19].  The coefficients kr (-1.7), kb 
(1.1 x 1015 cpd-1), and kc (5.739565 x 10-15 cpd) influence the shape, slope, and inflection 
point of the curves respectively [19].  
 
 
Microdamage Accumulation. Microdamage (D) is defined as the total crack length per 
section area of bone.  According to Martin [22], the rate of fatigue damage accretion is:  
RF DDD &&& −=          (14) 
 
 
where FD&  and RD&  are the damage formation and removal rates, respectively and are 
equal in a state of equilibrium.  The rate of damage formation was assumed to be a 
function of the mechanical stimulus Φ [22] which was defined as: 
 
Φ= DF kD& ,       (15) 
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where kD is the damage coefficient and Φ = εq x rl1 is the damage potential as described 
earlier.  For simplicity, the strain and peak strain (ε) are equivalent [19].  Martin’s model 
[22] also assumes that fatigue damage removal is proportional to the amount of damage 
that exists in the following relationship: 
 
SR DAcfAfD =& ,         (16) 
 
 
where Acf is the amount of BMUs found in the representative section per day, A is the 
area of all completed resorption areas, and fs is a damage removal specificity factor.  
Although damage is randomly distributed in the bone, it has been shown that damage 
initiates activation frequency [24], which improves the efficiency that damage is removed 
compared to that of random removal [19].  To account for this, the damage removal 
specificity factor was included and assumed to be 5 based on experimental results [19, 
24].  By assuming there is no net damage accumulation for the baseline conditions, the 
damage rate coefficient (kD) can be determined by setting FD&  equal to RD&  to obtain the 
following equation, 
 
000 /Φ= SD AfAcfDk ,       (17) 
 
 
where the initial equilibrium conditions are denoted by the subscript 0.   
 
 
Baseline model development.  Prior to applying bisphosphonate treatment to the model, 
equilibrium conditions were set based on the 1 year experimental control data.  Utilizing 
Nyman et al.’s [10] model for human vertebrae bone remodeling, physiological 
parameters were modified in order to adjust this model for cortical bone in canine ribs.  
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Pre-simulation parameters were calculated (Table 4) or estimated using data from 
experimental results obtained from the Indiana University School of Medicine or past 
studies.  The control values were obtained by running the model until the results reached 
equilibrium which took about 2000 iterations (or days).  As we were unable to obtain 
bone volume fraction values from 1 year experimental control animals, baseline bone 
volume fraction was assumed to be similar to 3 year values for cortical rib bone at 
BV/TV = 0.9675, which was obtained from histomorphometric analysis of 3 year 
samples.  The applied force and equivalent stress on the 100 mm2 cross-section from the 
1 cm3 representative bone sample to produce the desired BV/TV was set at 13.465 N and 
.13465 MPa respectively.  The resulting BV/TV was 0.9651, which was within range of 
the 1 year experimental control data. Both the force and stress were kept constant for the 
entire bisphosphonate treatment.  
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Table 4. Pre-simulation constants for bone remodeling in cortical bone prior to 
bisphosphonate treatment. 
Constant (units) Description Nominal Value Source 
Rc (mm) Cement line radius 0.19828147 [30] 
Rh (mm) Haversian canal radius 0.0551558 [30] 
Tr (days) Resorption period 25 [19] 
Tv (days) Reversal period 5 [19] 
Tf (days) Formation period 66* [30] 
phi0 (cpd) Initial mechanical stimulus 1.1479 x 10-14*† [31] 
por0 Initial Porosity 0.0324591*§ [24] 
kb (cpd-1) Activation frequency dose-response coefficient 1.1 x 10
15*†
 [19] 
kc (cpd) Activation frequency dose-response coefficient 5.739565 x 10
-15*
 [19] 
fs Damage removal specificity factor 5 [19] 
d0 (mm/mm2) Initial Damage 0.03578* [30] 
kr 
Activation frequency dose-response 
coefficient -1.7
*†
 [19] 
rl1 (cpd) Loading rate 21600*† [31] 
q Damage rate exponent 4 [19] 
kd (mm/mm2) Damage rate coefficient 9779300000 [19] 
Acf0 
(BMUs/mm2/day) Initial BMU activation frequency 0.0051
*
 [30] 
Acfmax 
(BMUs/mm2/day) 
Maximum BMU activation 
frequency 0.5 [19] 
Samax 
Maximum specific surface area, 
normalizing constant 4.1905 [19] 
*
 Unpublished data.  
§
 Measured data. 
† Estimated data. Constants kb and kr were determined by fitting sigmoidal curves based on the new  
  cortical dog rib data. rl1 was determined using a respiratory rate of 15 breaths per minute to obtain a   
  loading rate of 21600 cpd and phi0 was estimated from the number of loading cycles (rl1) and the    
  estimated strain.  
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Simulation of Bisphosphonate. After developing a baseline model that successfully 
simulated canine rib bone remodeling based on control experimental data, 
bisphosphonate treatment was incorporated into the program.  Bisphosphonate treatment 
was modeled for 3 years based on the assumption that the treatment would reduce two 
factors: activation frequency and BMU resorption area [10].  A potency variable P, where 
0 ≤ P ≤ 1, was used to model the effectiveness of bisphosphonates in suppressing 
remodeling.  The potency was derived from pharmacokinetic properties of 
bisphosphonate including its ability to suppress remodeling activation based on the 
chemical structure and dosage of the drug, its ability to bind to areas of bone resorption, 
its ability to be taken up by bone, and its mode of action [10] in the following equation: 
 
( )BMUNRsePP ×−−= τ1max ,        (18) 
 
 
where Pmax and τs are suppression coefficients that are intended to match the dosage and 
structure of the bisphosphonate.  These values were modified to match within 1 standard 
deviation, the mean experimental data for 1 and 3 year alendronate treatment of the bone 
volume fraction, activation frequency, and damage.  Although these values are not 
definitive, higher τ and Pmax values reflect a higher dose of alendronate and lower τ and 
Pmax values indicate a lower potency.  For the model, different iterations of Pmax values 
ranging between 0 and 1 and tau values between 1 and 20 were used to obtain the desired 
results.  These ranges were determined based on past studies [10].  P was then multiplied 
by the activation frequency in the equation, 
  
( )( ) Adamagedisuse SAcfAcfPAcf )()(1 +−= ,      (19) 
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to simulate bisphosphonate’s ability to suppress activation frequency [10].  
The reduction in the size of the BMU resorption cavities due to bisphosphonate 
treatment was also simulated by reducing the area resorbed. Starting with the control 
cement line radius of 0.198 mm, different resorption cavity areas ranging from 100% of 
control or no reduction, down to 50% of the control were evaluated to model 
bisphosphonate treatment:  
 
reducedareapercentRrarea c __)(_ 2 ∗= π .     (20) 
 
After testing all combinations of Pmax (0-1), tau (1-20), and the percent area reduced (0.5-
1) for bisphosphonate treatment, a Pmax = 0.3, a tau = 1, and a resorption area of 0.67 of 
the control value was used for ALN0.2 and a Pmax = 0.2, a tau = 1, and a resorption area 
of 0.625 was used for ALN1.0.  These values were used because the results from these 
combinations were found to be most closely within range of the BV/TV, Ac.f, and 
microdamage for the experimental 1 and 3 years of bisphosphonate treatment for each 
dosage.  
 
Numerical implementation.  The computational model was implemented in MATLAB 
(Appendix A).  This constitutive model relates two differential equations [Eqs. (9) and 
(14)] together for porosity and damage, respectively [19].  The mechanical stimulus Φ is 
the independent external force governing the model while the BMU activation frequency 
is dependent on Φ, along with the damage and the porosity [Eqs. (10), (12), and (13)].  
Previous studies have implemented a similar model using different numerical methods 
including the forward Euler method, and varying the time increments between 0.05 to 8 
days; however, the current numerical method was deemed sufficient for the present 
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model.  Using time steps smaller than 1 day did not significantly improve the accuracy, 
therefore, an iteration period of t = 1 day was used for this model because 
bisphosphonates are taken up fairly quickly [10]. 
 
2.5 Statistical Analysis 
To assess the dependence of the experimental bisphosphonate treatments for 1 
and 3 years, statistical analyses was performed to determine if there were variations 
between the treatment groups.  Using Minitab (Minitab Inc.; State College, PA), a one-
way analysis of variance (ANOVA) was performed for bone volume fraction, activation 
frequency, and microdamage for 1 and 3 years to compare treatment groups.  P-values 
less than 0.05 were considered statistically significant and signified that there was a 
significant difference between the treatment groups.  After completing an ANOVA, a 
Tukey post-hoc test was performed to compare individual pairs of treatment groups to 
determine where the significant difference lies between the paired means.  
A one sample t-test analysis was performed to compare the measured data to the 
simulated result for each treatment groups of bone volume fraction, activation frequency, 
and microdamage.  These results indicate whether the differences between the values are 
statistically significant. The null hypothesis was that the simulated results were equal to 
the measured results and was rejected for p < 0.05. 
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CHAPTER 3: RESULTS 
 
 
3.1 Experimental Bone Volume Fraction Measurements 
 
After measuring the porosity of each of the seventy-two sample slides using 
Bioquant, the bone volume fraction (BV/TV = 1 – porosity) was calculated.  Because two 
sections were cut from each of the thirty-six bone samples, the average BV/TV of each 
sample was calculated and is listed in Table 5 with its treatment group.  The final BV/TV 
values for each treatment group are summarized in Table 6.  These results were 
calculated by taking the mean with standard deviations of all the data from each of the 
three treatment groups.  
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Table 5. Measured 3 year data by treatment for bone volume fraction (BV/TV).* 
Sample # Treatment BV/TV 
60809 ALN1.0 0.9745 
60750 ALN1.0 0.9743 
59244 ALN1.0 0.9595 
59230 ALN0.2 0.9534 
59210 CON 0.9612 
59234 CON 0.969 
59238 ALN1.0 0.9618 
59211 ALN1.0 0.9695 
59235 ALN0.2 0.9724 
59257 CON 0.9674 
59219 ALN0.2 0.9618 
59315 CON 0.9592 
59256 ALN0.2 0.9592 
59258 ALN0.2 0.9677 
59231 ALN1.0 0.9636 
59236 ALN1.0 0.9558 
60657 ALN1.0 0.9589 
60628 CON 0.9717 
60034 CON 0.9654 
60592 ALN0.2 0.9677 
59536 ALN1.0 0.9596 
60642 ALN0.2 0.9783 
60593 ALN1.0 0.958 
60636 ALN0.2 0.9685 
59677 CON 0.9662 
60630 CON 0.9729 
60707 CON 0.9678 
60629 ALN0.2 0.9615 
60631 ALN0.2 0.973 
59239 ALN0.2 0.9639 
60641 ALN1.0 0.9751 
60632 CON 0.9767 
60643 ALN1.0 0.9597 
60645 ALN0.2 0.9697 
60644 CON 0.9631 
60667 CON 0.9675 
* Unpublished measured data 
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Table 6. Mean ± SD for the measured 3 year data. 
 CON (1ml/kg/day) Alendronate (0.20 
mg/kg/day) 
Alendronate 1.00 
mg/kg/day) 
Bone volume 
fraction (BV/TV) .96754 ± 0.00489 .96642 ± 0.00683 .96415 ± 0.00718 
 
 
 
3.2 Simulation Bone Volume Fraction Results 
For the simulation, the bone volume fraction (BV/TV) for both doses of 
alendronate (ALN0.2 mg/kg/day and ALN1.0 mg/kg/day) remained fairly constant 
throughout the 3 years of bisphosphonate treatment as was expected from the 
experimental data.  Figure 17 illustrates graphs for 1 and 3 years of ALN0.2 and ALN1.0 
treatment groups.  Although 1 year experimental control data was not obtained from the 
Indiana University School of Medicine, 3 year experimental control results were used 
instead because 1 and 3 year bone volume values were assumed to be similar.  The 
model’s results for the bone volume percentage were consistent with the experimental 
data (Table 7).   All simulated results matched within one standard deviation of the 
measured values.   
 
Table 7.  Model simulation and experimental measurements for bone volume fraction of the 
canine rib bone after 1 and 3 years by treatment. 
 Bone Volume Fraction 
 1 year 3 years 
 Experimental Simulated Experimental Simulated 
CON 0.968 ± 0.00489 0.9651 0.968 ± 0.00489 0.9651 
ALN0.2 0.966 ± 0.00683 0.9649 0.966 ± 0.00683 0.9651 
ALN1.0 0.964 ± 0.00718 0.9649 0.964 ± 000.718 0.9651 
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Figure 17. Simulation and experimental measurement results (mean and SD) for BV/TV for 
(a) control (CON) and ALN0.2 at 1 and 3 years and (b) control (CON) and ALN1.0 at 1 and 
3 years.  
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3.3 Simulation Activation Frequency Results 
 
The results of the computational model for the control and 1 year cortical rib data 
for the activation frequency were consistent with experimental measurements (Table 8).  
The model was able to predict the 1 year experimental results for both ALN0.2 and 
ALN1.0 along with the experimental results for ALN1.0 at 3 years, but overestimated the 
results for ALN0.2 at 3 years.  In the simulation, alendronate suppressed activation 
frequency for bone remodeling for both doses of drug and remained fairly constant over 
the span of 3 years of treatment.  While the simulation predicted that activation frequency 
remains mainly constant over the 3 years, the experiments show decreases between 1 and 
3 years.  Although not to a great degree, remodeling was suppressed in the model almost 
immediately after bisphosphonate treatment was introduced.  By 1.5 years, activation 
frequency had reached near constant for both alendronate doses. The representative 
graphs of both the simulated and experimental treatment data with its corresponding error 
bars can be seen in Figures 18.   
 
 
Table 8. Model simulation and experimental measurements for activation frequency of the 
canine rib bone after 1 and 3 years of ALN treatment. 
 Activation Frequency (BMUs/mm2/day) 
 1 year 3 years 
 Experimental Simulated Experimental Simulated 
CON 0.0384 ± 0.0290 0.0098 0.00902 ± 0.0077 0.0098 
ALN0.2 0.0361 ± 0.0322 0.009698 0.00153 ± 0.00215 0.0099 
ALN1.0 0.0202 ± 0.0134 0.009698 0.00521 ± 0.00792 0.01 
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Figure 18. Simulation and experimental measurement results (mean and SD) activation 
frequencies for (a) control (CON) and ALN0.2  for 1 and 3 years or treatment and (b)  
control (CON) and ALN1.0 for 1 and 3 years of treatment.  
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3.4 Simulation Microdamage Results 
 
The results of the computational model for the control, 1, and 3 year rib data for 
microdamage were consistent with experimental measurements (Table 9).  The model 
was able to predict an initial increase in damage for both bisphosphonate treatment doses 
before leveling off slightly after 1 year (Figure 19).  Microdamage begins to increase 
almost immediately after bisphosphonate treatment with a percent increase of 51.2% 
(ALN0.2) and 58.9% (ALN1.0) from the start of initiating bisphosphonate treatment 
(CON) to 3 years of treatment.  For ALN0.2, the modeled results show a percent increase 
of 8.3% from 1 to 3 years of bisphosphonate treatment and for ALN1.0, the modeled 
results show a percent increase of 10.2% from 1 to 3 years of bisphosphonate treatment.  
Although the simulated damage is not as high as the damage obtained from the 
experimental data, the overall trend correlates with experimental data which showed that 
the increase in microdamage at 3 years was not significantly different compared to the 1 
year results.  Both experimental and simulated microdamage results are shown for 1 and 
3 years of alendronate treatment in Table 9.  A condensed table of all parameters of 
interest (BV/TV, Ac.f, and damage) can be found in Appendix B. 
 
 
Table 9. Model simulation and experimental microdamage measurements in the canine rib 
bone after 1 year and 3 years of ALN treatment. 
 Microdamage (mm/mm2) 
 1 year 3 years 
 Experimental Simulated Experimental Simulated 
CON 0.0169 ± 0.0189 0.0129 0.0248 ± 0.0280 0.0129 
ALN0.2 0.0326 ± 0.0339 0.018 0.0449 ± 0.0273 0.0195 
ALN1.0 0.0332 ± 0.0393 0.0187 0.0408 ± 0.0216 0.0206 
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Figure 19. Experiment (mean ± SD) and simulation graphs for damage with 
bisphosphonate treatment starting at t = 0 (a) ALN0.2, (b) ALN1.0 
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3.5 Statistical Analysis 
 
A one-way ANOVA was performed on the bone volume fraction, activation 
frequency, and microdamage to test for significant differences between experimental 
treatment groups.  An ANOVA was only performed for experimental treatment groups so 
that any variation in the experimental results could be noted.  The results are displayed in 
Table 10 and Table 11 for the ANOVA. 
 
 
Table 10. 1 year ANOVA results for measured activation frequency and damage by 
treatment  
 CON ALN0.2 ALN1.0 P 
Activation Frequency 
(BMUs/mm2/year) 0.0384 ± 0.0290 0.0361 ± 0.0322 0.0202 ± 0.0134 0.196 
Damage (mm/mm2) 0.0169 ± 0.0189 0.0326 ± 0.0339 0.0332 ± 0.0393 0.374 
 
 
 
Table 11. 3 year ANOVA results for measured bone volume fraction, activation frequency, 
and damage by treatment 
 CON ALN0.2 ALN1.0 P 
Bone Volume Fraction 0.968 ± 0.00489 0.966 ± 0.00683 0.964 ± 0.00718 0.426 
Activation Frequency 
(BMUs/mm2/year) 0.00901 ± 0.0271 0.00153 ± 0.00215 0.00521 ± 0.00792 0.0286 
Damage (mm/mm2) 0.0228 ± 0.271 0.0449 ± 0.0273 0.0408 ± 0.216 0.0914 
 
 
All p-values for 1 year of alendronate treatment were greater than 0.05 which 
indicates that the variation between treatment groups were not significant.  The p-values 
for 3 year alendronate treatment showed that there is a significant difference between the 
treatment groups for the activation frequency which had a p-value of 0.0286.  To 
determine where the difference lies between each treatment, individual Tukey 
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comparisons were performed for the 3 year activation frequency.  The p-values for the 
Tukey comparisons show that the difference in treatment group found in the ANOVA test 
lies in the CON/ALN0.2 comparison with a p = 0.0039.  The results for the Tukey 
comparisons are presented in Table 12.  
 
 
Table 12. P-values for individual Tukey comparison for activation frequency for 3 years of 
treatment. 
Comparisons P 
CON and ALN0.2 0.0039 
CON and ALN1.0 0.2472 
ALN0.2 and ALN1.0 0.1337 
 
  
A separate comparison between the experimental results of ALN0.2 and ALN1.0 
for 1 and 3 years for activation frequency shows that all p-values are less than 0.05 which 
indicates that the 1 and 3 year data for both treatment groups are significantly different 
(Table 13).   A comparison between the experimental results for ALN0.2 and ALN1.0 for 
1 and 3 years for microdamage found that all p-values were greater than 0.05 which 
signifies that the 1 year experimental data is similar to the 3 year experimental data for 
each treatment group (Table 14).  
 
Table 13. P-values for activation frequency comparing 1 and 3 year experimental values. 
Comparisons P 
1 year CON vs 3 year CON 0.0026 
1 year ALN0.2 vs 3 year ALN0.2 0.0012 
1 year ALN1.0 vs 3 year ALN1.0 0.0029 
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Table 14. P-values for damage comparing 1 and 3 year experimental values. 
Comparisons P 
1 year CON vs 3 year CON 0.5427 
1 year ALN0.2 vs 3 year ALN0.2 0.3365 
1 year ALN1.0 vs 3 year ALN1.0 0.5651 
 
 
 
A one sample t-test analysis was performed to compare the measured 
experimental values to the simulated results for bone volume fraction, activation 
frequency, and damage.  The null hypothesis for each of the following t-tests was that the 
measured experimental value is equal to the simulated results, which represents the mean 
value.  For the bone volume fraction, the p-value of all treatment groups (CON, ALN0.2, 
and ALN1.0) for 1 and 3 years of treatment was greater than 0.05 so the null was not 
rejected, which implies that the measured and simulated results are statistically similar 
for all treatment groups (Table 15).  
 
Table 15. P-values for t-test for bone volume fraction for 1 and 3 years by treatment. 
 1 year 3 years 
 P P 
CON 0.112 0.112 
ALN0.2 0.458 0.518 
ALN1.0 0.726 0.657 
 
 
 
 
T-tests for the 1 year CON group for activation frequency resulted in a p < 0.05 
suggesting that there is a significant difference between the measured and simulated 
values with the 1 year experimental results being higher than the 1 year modeled result.  
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Similarly, a p value less than 0.05 was found for the ALN0.2 treatment group for 1 and 3 
years of treatment and for the ALN1.0 treatment group for 1 year (Table 16).  The null 
hypothesis was rejected for these cases.  The 3 year ALN1.0 treatment group for 
activation frequency resulted in a p > 0.05 indicating a similarity between the measured 
and simulated results, so the null hypothesis was not rejected.  
 
 
Table 16. P-values for t-test for activation frequency for 1 and 3 years by treatment. 
 1 year 3 years 
 P P 
CON 0.006 0.7324 
ALN0.2 0.016 0.0001 
ALN1.0 0.02 0.06 
 
 
T-test results for microdamage (Table 17) yielded p values greater than 0.05 for 
all 1 year treatment groups and the CON at 3 years, which indicate that the null was not 
rejected and that the measured and simulated results are statistically similar.  For ALN0.2 
and ALN1.0 treatment groups at 3 years, p = 0.008, which implies that there is a 
significant difference between the measured and simulated results for both cases with the 
experimental damage result higher than the modeled result for both treatment groups.  
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Table 17. P-values for t-test for damage for 1 and 3 years by treatment. 
 1 year 3 years 
 P P 
CON 0.484 0.2335 
ALN0.2 0.164 0.008 
ALN1.0 0.227 0.008 
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CHAPTER 4: DISCUSSION 
 
 
 
 
Osteoporosis is a skeletal disease that occurs when the amount of bone resorption 
exceeds that of bone formation.  Without treatment, bone becomes more porous and 
fracture risk is increased.  Bisphosphonates are commonly used to treat bone diseases 
such as osteoporosis by reducing resorption activity [17].  The objective of this study was 
to modify a previous mathematical model for bone remodeling which incorporated a 
bisphosphonate algorithm, in order to simulate the effects of alendronate on canine rib 
remodeling and microdamage after 1 and 3 years of treatment.  To do so, empirical data 
for 1 and 3 year studies were supplied by Allen et al. [24, 30] from the Indiana University 
School of Medicine, and utilized to confirm the accuracy of the model.  The current study 
uses the results from the control experimental data for dog ribs as a baseline to create a 
model that simulates the effects of ALN for a 3 year period.  The importance of 
developing a model is to predict long term outcomes without having to carry out long 
term experimental tests.  Because canine bone remodeling dynamics are similar to human 
bone remodeling, this canine model can be used to draw parallels to the drugs effects on 
human bones [32].  
 
4.1 Bone Volume Fraction 
 
The model predicts a slight increase in the bone volume fraction for both 
treatment doses from one to three years.  The results comply with the original assumption 
that the 1 and 3 year experimental data were similar, which allowed the three year bone 
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volume measurements to be used in place of the one year data.  To validate this 
assumption, an ANOVA test was performed between experimental treatment groups 
(CON, ALN0.2, and ALN1.0).  The p-value of 0.426 indicates that the results from each 
treatment group are not significantly different.  Results from the computer model indicate 
that the BV/TV for both doses of alendronate was fairly constant throughout the 3 years 
of bisphosphonate treatment and the simulation was able to successfully match all 
experimental data within one standard deviation.  The small increase from one to three 
years of treatment denotes a decrease in the bone’s porosity which is due to the 
suppression of osteoclast activity.  This is consistent with studies that have shown an 
increase in bone mass following treatments of bisphosphonate [10].   
 
4.2 Activation Frequency 
 
The model results for activation frequency for the control, 1 year ALN0.2 and 
ALN1.0, and 3 year ALN1.0 were within range of the experimental data; however, 
activation frequency for ALN0.2 for 3 years was not consistent with the experimental 
measurements.  As predicted by past experimental studies, bisphosphonate usage 
suppressed bone remodeling for both modeled doses of alendronate.  While the 
simulation was able to show decreases in bone remodeling for both treatment doses after 
1 year of treatment, the decrease was not nearly as drastic as the results seen in the 
experimental study and remained fairly constant between 1 and 3 years, which is in 
contrast to the experimental results.  Despite this, the model was able to match all but one 
of the experimental data, which overestimated ALN0.2 for the three years of treatment.  
The one-way ANOVA for activation frequency for 3 years of treatment found that there 
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was a discrepancy between the three treatment groups (CON, ALN0.2, and ALN1.0) with 
a p-value less than 0.05.  This result shows that there is a statistically significant 
difference between the 3 year experimental treatment groups and that there is less than a 
5% chance of obtaining these results assuming the null hypothesis is true.  Performing a 
Tukey comparison between individual 3 year experimental treatment groups showed that 
the difference came from the control group.  The current model predicts that the 
activation frequency for the 1 and 3 year control treatment is similar and did not account 
for the actual change seen in the experimental measurements.  The unpublished 3 year 
study by Burr et al. [24] obtained a control activation frequency of 0.00901 
BMUs/mm2/day, which is 4 times less than the 1 year control activation frequency used 
for the model (0.03841 BMUs/mm2/day).  This disparity in 1 and 3 year control values 
may explain some of the inconsistencies of the model results.  The one-sample t-test 
statistical analysis determined that 3 year CON and ALN1.0 for the measured and 
simulated results are similar; however, all 1 year treatment groups (CON, ALN0.2, and 
ALN1.0) and the 3 year ALN0.2 for the measured and simulated results are statistically 
different with p-values less than 0.05.  Although the 1 year measured and simulated 
results were found to be statistically different, all 1 year modeled results were within 1 
standard deviation of the experimental results. 
 
4.3 Microdamage Accumulation 
 
 The effect of bisphosphonates on microdamage accumulation has been a major 
issue concerning the long term use of the drug because increases in microdamage can 
lead to bone fragility.  Studies have shown a relationship between the suppression of 
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bone remodeling and microdamage accumulation over a treatment period of 1 year [17, 
33].   Because patients generally undergo osteoporosis treatment drugs for longer than 1 
year, it is important to determine the effects of the drug for a longer time period.  Three 
year studies performed by Allen et al. [18, 24] show that although treatment group 
microdamage levels increase above the control group, damage does not significantly 
increase after 1 year of alendronate treatment.   The computer model predicts that damage 
accumulation is greatest early during bisphosphonate treatment, due to the initial 
suppression of bone resorption, and eventually reaches a new equilibrium level after 1 
year.  Although the increase in damage is not as high as the measured results, the overall 
shape of the curve is consistent.  The increase in damage was previously thought to 
impair the mechanical properties of bone [34]; however, recent experimental studies 
show that while the initial increase in microdamage may contribute to alterations in bone 
properties at 1 year of treatment, other factors like increased mineralization and bone 
volume appear to impede the harmful effects of damage accumulation in the long run 
[24].  The simulation results are consistent with the experimental data, which suggest that 
damage increases up to 1 year of treatment and then levels off thereafter. The results of 
the simulation suggest that since bisphosphonates do not cause a further increase in 
microdamage accumulation after 1year of treatment, ALN may not lead to increased bone 
fragility associated with microdamage long term.  These results are seen in 3 year 
experimental studies as well.   
Logically, it makes sense that microdamage increases until a new equilibrium is 
reached between the amount of damage formation and damage removal because 
bisphosphonates inhibit bone remodeling.  The computational model results for the 1 and 
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3 year rib data for all treatment groups were consistent with experimental measurements.  
One-sample t-test statistical analyses confirm that the simulated 1 year microdamage 
results for the CON, ALN0.2, and ALN1.0 treatment groups were similar to the 1 year 
experimental measurements with p > 0.05.  The 3 year simulated control group also 
showed similarities to the 3 year experimental control; however, the t-tests for the three 
year ALN0.2 and ALN1.0 treatment groups rejected the null hypothesis with p values 
less than 0.05.  Although the ALN0.2 and ALN1.0 treatment groups did not satisfy the 
null hypothesis in this case, as observed in the graph (Figure 13), both results are within 1 
standard deviation of the experimental measurement data.   
 
4.4 Limitations and Future Model Considerations 
 
The present study was able to simulate the effects of alendronate treatment on 
bone remodeling; however, limitations to the model must be considered when 
interpreting the results.  Although the general mechanisms of bisphosphonate are 
simulated in the model, the entire range of the drugs response is not taken into account 
due to its complexity and the lack of understanding of the exact mechanism of action that 
bisphosphonates have in the body.  Theoretical models require many of assumptions and 
guesswork which involve verifying the results of the model with experimental data.  
As indicated by Hernandez et al. [16], bone mineralization is a major contributor 
of increases in BMD than simply decreasing area resorbed as done in the current model.  
Bisphosphonate treatment reduces the bone turnover rate in bone which allots more time 
for mineralization to take place thus allowing secondary mineralization to play an 
important role in BMD.  By limiting the number of osteoclasts that resorb bone, bone is 
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allowed more time to mineralize before being resorbed thus resulting in increases in bone 
mass.  Because changes in resorption area and mineralization are both factors in 
increased BMD, future models should include both methods when determining the effects 
of bisphosphonates on bone remodeling.  
Another possible improvement is the elastic modulus and the bone volume 
fraction relationship.  For the current model, the equation was estimated using only the 
empirical data given for the 3 year bisphosphonate dog rib study.  If more information 
was available for the 1 year experimental studies including the elastic modulus and the 
bone volume fractions from each treatment group, the modulus-BV/TV relationship 
could be improved by comparing the 1 and 3 year results and creating a more accurate 
relationship. 
The current model assumes that the ability of BMUs to target damage removal or 
the specificity factor fs is constant; but, this is not necessarily accurate since areas of 
resorption with microdamage have been shown to be reduced with alendronate treatment 
[10].  If fs were to be varied according to the microcrack initiation, damage removal may 
decrease compared to the current results.   
Also, bone formation was assumed to be normal prior to bisphosphonate 
treatment. However, this does not accurately represent osteoporotic bone which 
corresponds to higher levels of bone resorption and a decrease in bone formation. 
Modeling osteoporotic bone from the start could greatly improve the current model. 
Another limitation of the current model is that it was assumed that the control 
experimental result for bone volume fraction, activation frequency, and microdamage 
were assumed to be the same for 1 and 3 year.  In actuality, the control for 1 and 3 year 
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experimental studies vary greatly.  This assumption will affect the modeled activation 
frequency result most, as this 3 year experimental control varied greatly compared to the 
1 year experimental control data.  The model would significantly benefit by modifying 
the program to take this into account.  By allowing the simulation to reach the three year 
experimental control, the 3 year model results may improve and more accurately 
represent the 3 year experimental results.   
Furthermore, the current study only simulates remodeling under a constant 
applied stress in a representative section of bone rather than modeling the entire rib bone 
or developing finite element models that could allow a more accurate remodeling 
response by allowing more precise loading conditions and provide better analysis of 
different strain rates on different sections of bone.  Making these modifications in the 
model could greatly improve future understanding of bisphosphonates and its long term 
effects on bone.  
 
4.5 Conclusion 
 
 The goal of the study is to develop a computational model to determine the effects 
of bisphosphonate treatment on remodeling dynamics by matching the results of 1 and 3 
year experimental data for bone remodeling and damage in a canine rib model.  The 
results from the simulation are as follows: 
• Previous experimental studies have shown that bisphosphonate treatment reduces 
fracture risk by increasing bone mass [17, 33].  The model predicted a slight 
increase in bone volume fraction for both doses (ALN0.2 and ALN1.0) of 
bisphosphonate treatment over a three year period.    
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• The purpose of taking alendronate is to reduce bone porosity by decreasing bone 
resorption.  Bisphosphonates do this by suppressing osteoclast activity and in 
effect bone remodeling which decreases the activation frequency as shown in the 
model.  
 Although the degree of reduction in activation frequency for the computer 
model did not match the value seen in the experiments, 1 and 3 year 
ALN1.0 and 3 year ALN1.0 treatment doses were within range of the 
measured results.   
• Because bisphosphonates suppress bone remodeling, microdamage accumulation 
has been shown to increase at 1 year of treatment [17, 18, 24, 33]; however, 3 
year experimental results show that although microdamage increases after initial 
bisphosphonate treatment, damage does not continue to increase and rather 
reaches a plateau after around 1 year. 
 The model was able to reflect the recent 3 year canine studies performed 
by Allen et al. [18, 24]. All simulated model results for microdamage 
support the findings obtained from previous experimental studies.  
 
Future experimental studies investigating longer time periods of bisphosphonate 
treatment are necessary in order to enhance and validate the computer model to better 
predict the long term effects of bisphosphonate usage.  Longer experimental studies are 
also needed to better understand the relationship between bone remodeling suppressant 
drugs and bone health.  Improved computational models are also beneficial to more 
accurately predict bone remodeling.  This is important in order to ensure that the long 
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term effects of alendronate treatment are safe and effective for the use in osteoporotic 
patients.  These simulations will help in developing improved methods of predicting 
bisphosphonate treatment on bone as well as determine if the long term effects of 
bisphosphonate usage will indeed increase bone mass and reduce fracture risk.  The 
understanding of the effects of bisphosphonate treatment on dog ribs can also aid in 
developing better models to simulate the effects of bisphosphonate treatment in humans. 
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APPENDIX A: MATLAB CODE 
 
 
 
 
%Bone Remodeling Simulation with Bisphosphonate Treatment 
%modified from Jeffery Nyman 
%Emily Huang 7May2009 
% 
clear 
clc 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
 
%% Remodeling parameters %% 
  
Rc = 0.19828147;                           % Cement line radius 
Rh =.0551558;                                 % Haversian canal radius 
Tr = 25;                                                   % Resorption period 
Tv = 5;                                        % Reversal period 
Tf = 66;                                           % Formation period  
trab1 = 0.2;                                                 % Porosity partition for cortical to trabecular  
   % bone: Change resorption area & Disuse 
trab2 = 0.097267787;                          % Porosity partition for cortical to trabecular bone:     
       % Change in stiffness constants 
phi0 = 0.00000000000001147913;            % Equilibrium stimulus 
por0 = 0.0324591;                             % initial cortical porosity (from 3 year rib study) 
%por0 = 0.2;                                               % Initial trabecular porosity (for human vertebra  
                % bone) 
sa0 = ((((28.8*por0-101)*por0+134)*por0-93.9)*por0+32.1)*por0;   % Initial surface area 
phc = 0.0324591;                                  % Adjusts resorption rate to match apposition rate  
% for cortical bone (i.e. assumes resorption          
% process includes void spaces 
                                      
%% Activation frequency conditions  %% 
% Describes Ac.f versus disuse and Ac.f versus damage curves % 
  
Acfmax1 = 0.5;                               % Maximum Ac.f due to damage 
Acfmax2 = 0.5;                               % Maximum Ac.f due to disuse 
samax = 4.1905;                              % Normalizes specific area 
Acfdis0 = 0.0;                                  % Equilibrium Ac.f for disuse 
Acfdam0 = 0.0224693284;                    % Equilibrium Ac.f for damage 
Acf0 = (Acfdam0 + Acfdis0)*sa0/samax ;    % Equilibrium Ac.f 
kb = 1100000000000000;                       % Remodeling coefficient (obtained from curve      
    % fitting clinical data) 
kc = phi0/2;                                  % Remodeling coefficient (obtained from curve     
  % fitting clinical data) 
  
%% Damage conditions  %% 
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fs = 5;                                       % Damage repair factor 
d0 = 0.03578;                                % Initial equilibrium damage 
if por0 <= trab1 
   kd = d0*Acf0*(pi*Rc^2)*fs/phi0 ;       % Equilibrium damage constant 
else 
   kd = 0.5*d0*Acf0*(pi*Rc^2)*fs/phi0; 
end 
  
kr = -1.7;                                  % Remodeling coefficient (obtained from curve        
% fitting clinical data) 
  
%% Mechanical conditions %% 
  
Area = 100;                                 % Cross-sectional area of bone 
rl1= 21600;                                 % Frequency of loading in no. of cycles per day 
q = 4;                                      % Exponent of mechanical stimulus 
change = 0;                                % Percent change in force 
chgper = 1;                                % Time period of force change 
days = 2000;                                % Time length to equilibrium 
bis_days = 365*3;                          % Time length for bisphosphonate  
dt = 1;                                     % Time step; One day 
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
%% Prior conditions before start of simulation %% 
  
for t=1:(Tr+Tv+Tf) 
   por(t) = por0;                           % Porosity 
   if por(t) <= trab2 
      modulus(t) = 6634*(1-por(t))^5.49; %Stiffness of bone if cortical 
   else 
      modulus(t) = 6634*(1-por(t))^5.49; %Stiffness of bone if trabecular 
   end 
    
   Phi(t) = phi0;                           % Mechanical stimulus 
   strain(t) = (phi0/rl1)^0.25;            % Principal strain 
   stress(t) = modulus(t)*strain(t);      % Principal stress 
   Force(t) = stress(t)*Area;              % Force on bone 
   SA(t) = sa0/samax;                      % Normalizes Ac.f by available surface area 
   Df(t) = kd*phi0;                        % Damage formation rate 
   Dr(t) = d0*Acf0*(pi*Rc^2)*fs;             % Damage removal rate 
  
   if por(t) > trab1 
       Dr(t) = 0.5*Dr(t); 
   end 
  
   D(t) = d0;                        % Damage 
   NfBMU(t) = Acf0*Tf;                            % No. of refilling BMUs 
   NrBMU(t) = Acf0*Tr;                     % No. of resorbing BMUs 
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   if por(t) <= trab1 
       Qf(t) = pi*(Rc^2-Rh^2)/Tf;             % Mineral apposition rate 
       Qr(t) = pi*Rc^2/Tr;                          % Mineral resorption rate 
       QrNr(t) = (1-phc)*Qr(t)*NrBMU(t); % Amount bone removed 
       QfNf(t) = Qf(t)*NfBMU(t);               % Amount of bone added 
   else 
       Qf(t) = 0.5*pi*Rc^2/Tf; 
       Qr(t) = 0.5*pi*Rc^2/Tr; 
       QrNr(t) = Qr(t)*NrBMU(t); 
       QfNf(t) = Qf(t)*NfBMU(t); 
   end 
    
   Qnet(t) = QfNf(t)-QrNr(t);                  % Difference between mineral added and mineral 
removed 
   Acfdam(t) = Acfdam0;                     % Ac.f due to damage 
   Acfdis(t) = Acfdis0;                            % Ac.f due to disuse 
   Acf(t) = 0.03841;                                % Total inital Ac.f 
   TIME(t) = t; 
end 
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
 
%% Constants for bisphosphonate treatment %% 
  
%Pmax = 0; 
Pmax = .2;                                    % Pmax values between 0 and 1 
%Pmax = 1;  
tau= 1;                                     % Tau values between 1 and 20 
  
%percent_area_reduced = 1;        % percent area of CON area reduced b/w 0.5 and 1 
% percent_area_reduced = 1/1.1;        
% percent_area_reduced = 1/1.2;         
% percent_area_reduced = 1/1.3;         
% percent_area_reduced = 1/1.4;      
% percent_area_reduced = 1/1.5;         
percent_area_reduced = 1/1.6;            
% percent_area_reduced =1/1.7;        
% percent_area_reduced = 1/1.8;         
% percent_area_reduced = 1/1.9;         
% percent_area_reduced = 1/2;                   
  
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
%% Simulation %% 
  
for t=(Tr+Tv+Tf+1):((days)+ bis_days) 
   TIME(t) = t; 
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%% Mechanical conditions update %% 
   if por(t-1) <= trab2 
      modulus(t) = 6634*(1-por(t-1))^5.49;  %Stiffness of bone if cortical 
   else 
      modulus(t) = 6634*(1-por(t-1))^5.49;  %Stiffness of bone if trabecular 
   end 
  
Force(t) = 13.465;         
stress(t) = Force(t)/Area;                % Stress on bone 
strain(t) = stress(t)/modulus(t);      % Strain on bone 
  
%% Porosity update %% 
 
Phi(t) = (strain(t)^q)*rl1;                %Calculate current stimulus 
     
if por(t-1) <= 0.2 
area_f = pi*(Rc^2-Rh^2);         %Formation area of cortical bone (Cement  
% line to Haversian canal) 
        if (t <= days)                        %Inital period  
            area_r = pi*Rc^2;                %Resorption area if cortical 
        else 
            area_r = (pi*Rc^2) * percent_area_reduced ;  %Resorption area if cortical & on        
 % Bisphosphonate 
        end 
else 
area_f = 0.5*pi*Rc^2;                      %Formation area of trabecular         
% bone (half of osteon area w/o       
% pore) 
      if (t <= days)                           %Initial period 
           area_r = 0.5*pi*Rc^2;                %Resorption area if trabecular 
       else 
           area_r = (pi*Rc^2) * percent_area_reduced;    %Resorption area if trabecular on        
 % bisphosphonate 
       end 
end 
  
%% Calculate change in damage level and update %% 
  
       Df(t) = kd*Phi(t);                   %Damage formation rate 
       Dr(t) = D(t-1)*Acf(t-1)*area_r*fs;     %Damage removal rate 
       D(t) = D(t-1) + (Df(t) - Dr(t))*dt;    %Damage update 
  
%% Calculate demand for new BMUs (Ac.f) %% 
        
       if D(t) >= d0 
            Acfdam(t) = (Acf0*Acfmax1)/(Acf0+(Acfmax1-Acf0)*exp(kr*Acfmax1*(D(t-1)- 
d0)/d0));       %Damage stimulus 
       else 
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            Acfdam(t) = Acf0*D(t-1)/d0; 
       end 
        
     
       if Phi(t) >= phi0 
            Acfdis(t) = 0;                     % No demand for additional              
 % remodeling if not in disuse 
       else 
            Acfdis(t) = Acfmax2/(1+exp(kb*(Phi(t)-kc)));    % Demand for remodeling when  
 % bone is in disuse 
       end 
  
       sa = ((((28.8*por(t-1)-101)*por(t-1)+134)*por(t-1)-93.9)*por(t-1)+32.1)*por(t-1);    
%Surface area 
       SA(t)= sa/samax; 
       Acf(t) = (Acfdam(t) + Acfdis(t))*SA(t);               %Update Ac.f 
  
        
 %% Calculate daily amount of bone removed per resorbing BMU %% 
 %% Include less refilling on trabecular surfaces in disuse %% 
  
      ab = area_f;                             % Formation area 
      ac = area_r;                                      % Resorption area        
  
      Qf(t) = ab/Tf; 
      Qr(t) = ac/Tr; 
  
      if Phi(t) < phi0  
          if por(t-1) > trab1  
                 Qf(t) = (0.5 + 0.5*(Phi(t)/phi0))*Qf(t);     % For trabecular bone, formation      
% rate decreases in disuse 
          end 
      end 
  
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%    Bisphosphosphonate effect      %% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
     if (t > days)                                             %Bisphosphonate treatment period 
          P = Pmax*(1-exp(-1*tau*NrBMU(t-1))); 
          % P = 1;                                             % Remodeling is completely               
% suppressed 
Acf(t)=(1-P)*(Acfdam(t)+Acfdis(t))*SA(t);           % Bisphosphonate suppressed                      
    % activation frequency 
     end 
  
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%% Calculate number of refilling BMUs for current day %% 
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%% Calculate number of resorbing BMUs for current day %% 
  
      NfBMU(t) = NfBMU(t-1) + (Acf(t-Tr-Tv) - Acf(t-Tr-Tv-Tf))*dt; 
      NrBMU(t) = NrBMU(t-1) + (Acf(t) - Acf(t-Tr))*dt; 
  
       
      if NfBMU(t) < 0 
         NfBMU(t) = 0; 
      end 
       
      if NrBMU(t) < 0 
         NrBMU(t) = 0; 
      end 
     
              
%% Calculate net amount of bone added per day %% 
  
       QfNf(t) = NfBMU(t-1)*Qf(t-1) + (Acf(t-Tr-Tv)*Qf(t-Tr-Tv) - Acf(t-Tr-Tv-Tf)*Qf(t-Tr-Tv-Tf))*dt;    
% amount of bone added 
       QrNr(t) = NrBMU(t-1)*Qr(t-1) + (Acf(t)*Qr(t) - Acf(t-Tr)*Qr(t-Tr))*dt;                            
% amount of bone removed 
        
       if por(t-1) <= 0.20 
           Qnet(t) = QfNf(t) - (1-phc)*QrNr(t); 
       else 
           Qnet(t) = QfNf(t)-QrNr(t); 
       end 
  
  
%% Calculate change in porosity %% 
  
por(t) = (por(t-1) - Qnet(t))*dt; 
   
    uplim = 0.99; 
    blim = 0.0; 
  
if por(t) >= uplim; 
   por(t) = uplim; 
elseif por(t) <= blim; 
   por(t) = blim; 
end 
  
  
end 
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
figure(1); 
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plot(TIME,por); 
title('Porosity'); 
xlabel('Time (days)'); 
ylabel('Void space/Total area'); 
figure(2); 
plot(TIME,Acf); 
title('Ac.f'); 
xlabel('Time (days)'); 
ylabel('Activation frequency (#  BMU/day/mm2)'); 
figure(3); 
plot(TIME,Phi); 
title('Phi'); 
xlabel('Time (days)'); 
ylabel('Mechanical stimulus'); 
figure(4); 
plot(TIME,D); 
title('Damage'); 
xlabel('Time (days)'); 
ylabel('Cr.S.Dn (mm/mm2)'); 
figure(5); 
plot(TIME,Qnet); 
title('change in bone'); 
xlabel('Time (days)'); 
ylabel('delta Porosity'); 
figure(6); 
plot(TIME, kd); 
  
%% Outputs %% 
BoneVolumeFraction = (1-por(t)) 
ActivationFrequency = Acf(t) 
Damage = D(t) 
  
  
for t=1:days + bis_days 
Dataout(t,:) = [TIME(t),por(t),Phi(t),strain(t),stress(t),Force(t),SA(t),Df(t),Dr(t),D(t), 
NfBMU(t),NrBMU(t),Qf(t),Qr(t),QrNr(t),QfNf(t),Qnet(t),Acfdam(t),Acfdis(t),Acf(t),kd]; 
end 
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APPENDIX B: COMPREHENSIVE TABLE OF ALL SIMULATED AND MEASURED DATA 
 
 
 
 
 
 CON ALN0.2 (1 YEAR) ALN0.2 (3 YEARS) ALN1.0 (1 YEAR) ALN1.0 (3 YEARS) 
 
Experimenta
l 
Simulate
d 
Experimenta
l Simulated 
Experimenta
l Simulated Experimental Simulated Experimental Simulated 
           
BV/TV 0.968 ± 0.00489 0.9651 
0.966± 
0.00683 0.9649 
0.966 ± 
0.00683 0.9651 
0.964 ± 
0.00718 0.9649 
0.964 ± 
0.00718 0.9651 
Ac.f 
(BMU’s/mm
2/day)  
0.0384 ± 
0.0290 0.0098 
0.0361 ± 
0.0322 0.009698 
0.00153 ± 
0.00215 3.6135 
0.0202 ± 
0.0134 0.009698 
0.00521 ± 
0.00792 0.01 
Damage 
(mm/mm2) 
0.0169 ± 
0.0189 0.0129 
0.0326 ± 
0.0339 0.018 
0.0449 ± 
0.0273 0.0195 
0.0332 ± 
0.0393 0.0187 
0.0408 ± 
0.0216 0.0206 
 
 
 
 
 
